



Does the use of Povidone Iodine Suppositories decrease the infective complications of TRUS guided prostate biopsies? A randomized prospective study

Thesis

Submitted for Partial Fulfillment of Master's Degree in Urology

Вy

Mohammad Saad Abdulbaki Hafez

M.B.B.Ch, of Medicine and Surgery

Supervised by

Prof. Dr. Hassan Sayed Shaker

Professor of Urology Faculty of Medicine - Ain Shams University

Dr. Ahmed Mohamed Mohamed Emam

Lecturer of Urology Faculty of Medicine - Ain Shams University

Dr. Mohammed Husien Badawy

Lecturer of Urology Theodor Bilharz Research Institute

> Faculty of Medicine Ain Shams University 2019.



سورة البقرة الآية: ٣٢

Acknowledgment

First and foremost, I feel always indebted to **ALLAH**, the Most Kind and Most Merciful.

I'd like to express my respectful thanks and profound gratitude to **Prof. Dr. Hassan Sayed Shaker**, Professor of Urology Faculty of Medicine - Ain Shams University for his keen guidance, kind supervision, valuable advice and continuous encouragement, which made possible the completion of this work.

I am also delighted to express my deepest gratitude and thanks to **Dr. Mohammed Husien Badawy**, Assistant Professor of Urology Theodor Bilharz Research Institute, for his kind care, continuous supervision, valuable instructions, constant help and great assistance throughout this work.

I am deeply thankful to **Dr. Ahmed Mohamed**Mohamed Emam, Lecturer of Urology Faculty of Medicine Ain Shams University, for his great help, active participation and guidance.

Mohammad Saad Abdulbaki Hafez

List of Contents

Title	Page No.
List of Abbreviations	5
List of Tables	6
List of Figures	7
Introduction	1
Aim of the Work	12
Review of Literature	
Anatomy of the Prostate	13
 Transrectal Ultrasonographic Anatomy of the P 	rostate.21
 Patient Preparation & Antibiotic Prophylaxis 	26
Patient Positioning	29
■ Technique	30
Complications	35
Patients and Methods	39
Results	46
Discussion	58
Summary	72
Conclusion	74
References	75
Arabic Summary	—

List of Abbreviations

Abb.	Full term
BPH	. Benign prostatic hyperplasia
CRP	. C reactive protein
CZ	. Central zone
DM	. Diabetes mellitus
DRE	. Digital rectal examination
E. coli	. Escherichia coli
HTN	. Hypertension
PSA	. Prostatic specific antigen
PZ	. Peripheral zone
TLC	. Total leucocytic count
TRUS	. Transrectal ultrasound
TRUS-Bx	. Transrectal ultrasound guided prostate biopsy
TURP	. Transurethral resection of the prostate
TZ	. Transitional zone
US	. Ultrasound
UTI	. Urinary tract infection

List of Tables

Table No.	Title	Page No.
Table (1):	Comparison of patient character values between treatment and con-	
Table (2):	Comparison between mean values post procedure CRP within each gr	-
Table (3):	Comparison between mean values post procedure TLC within each gr	-
Table (4):	Comparison between infectious coin treatment and control groups	-
Table (5):	Rectal swabs and post proce cultures in patients with post infectious complications.	procedure
Table (6):	Comparison of rectal swab culture treatment and control groups	
Table (7):	Infectious complications among or resistant rectal swab population	*
Table (8):	Comparison of bleeding complication treatment and control groups	

List of Figures

Fig. No.	Title f	Page No.
Fig. (1):	Normal prostate in vertical section	13
Fig. (2):	Cross section of prostate	
Fig. (2):	Zonal anatomy of the prostate	
_		
Fig. (4):	Arterial supply of the prostate	
Fig. (5):	The veins of the right half of the male pel	
Fig. (6):	Normal prostate TRUS images	
Fig. (7):	Classic gray-scale transrectal ultrasonogimaging of the prostate	
Fig. (8):	Classic hypoechoic peripheral zone lesion	
Fig. (9):	American Urological Association 2014	
	Practice Policy Recommended Antibiot Routine Prostate Biopsy	ics for
Fig. (10):	Patient positioning in left lateral decubir	
Fig. (11):	Measurement of prostate volume in axis sagittal planes	ial and
Fig. (12):	Endorectal probe	
Fig. (13):	Ultrasound machine	
Fig. (14):	10 core prostate biopsy	
Fig. (14):	Mean values of age, prostate size, and l	
F1g. (19):	treatment and control groups	
Fig. (16):	DM and HTN distributions in treatme control groups.	
Fig. (17):	Mean values of pre and post procedur within each group.	
Fig. (18):	Mean values of pre and post procedur within each group	e TLC
Fig. (19):	Infectious complications in treatment control groups	t and

List of Figures Cont...

Fig. No.	Title	Page No.	
Fig. (20):	Rectal swab cultures in treatment an groups		4
Fig. (21):	Bleeding complications in treatment control groups	ent and	
Fig. (22):	Studies showing fluoroquinolone resistant flora		9

INTRODUCTION

rostate cancer is the second most common cancer and the sixth leading cause of cancer deaths worldwide with an estimated 899,000 cases and 258,000 deaths annually. By 2030, these rates are anticipated to increase to 1,700,000 and 499,000 (Center et al., 2012).

Prostate cancer has been the most common noncutaneous malignancy in U.S. men since 1984, now accounting for 27% of all such cancers (Siegel et al., 2014).

In Europe, prostate cancer represents the most common non skin cancer among elderly males (>70 years) being of higher incidence in northern and western Europe (200 per 100.000) (Arnold et al., 2015).

Prostate cancer incidence varies according to Race/ ethnicity with African-Americans incidence rates 59% higher than incidence rates among whites. African-Americans and Jamaicans of African descent have the highest incidence rates in the world (Siegel et al., 2014).

Prostate cancer is rarely diagnosed in men less than 50 years of age, accounting for only 2% of all cases. Prior to the PSA era, median age at diagnosis was 70 years, falling to 67 years over the past decade, with 63% diagnosed after age 65 (Ries et al., 2008).



Diagnosing prostate cancer rely on prostatic specific antigen (PSA) testing, digital rectal examination (DRE) and obtaining prostate biopsy for histopathological examination by transrectal Ultrasound guidance (TRUS) or Magnetic Resonance imaging diffusion techniques.

Prostate biopsy:

Obtaining prostate biopsy is the cornerstone in managing prostate cancer. It could be done using transrectal ultrasound guidance, transperineal ultrasound guidance or multiparametric MRI targeting. TRUS guided prostate biopsy is more feasible and less expensive than MRI.

TRUS of the prostate was first described by Watanabe and colleagues 1968. TRUS evolved in the last 2 decades to become a fundamental tool in urology specially in management of prostate cancer which relies on many image guided interventions including prostate biopsy for both diagnosis and active surveillance, brachytherapy, cryotherapy and highintensity focused ultrasound (US). TRUS guided placement of radiofrequency markers is mandatory in radiation therapy for real-time tumor tracking of the prostate (Linden et al., 2009; Das et al., 2014). Recently, a new use of TRUS is being implemented by injecting Polyethylene glycol hydrogel into anterior perirectal fat to decrease radiotoxicity in radiation therapy (Strom et al., 2014). TRUS has its valuable usage in some other benign cases as in evaluating treatment options in



benign prostatic hyperplasia (BPH) and some cases of infertility.

The use of digitally directed prostate biopsy, common until the late 1980s, evolved into the expanded clinical use of TRUS-directed prostate biopsies. TRUS-guided systematic sextant (six cores) biopsy protocol was described by Hodge and Associates (1989).

Now the standard technique is 10-12 biopsies (*Donovan* et al., 2003).

AIM OF THE WORK

The aim of this study is to assess the prevalence of different organisms among rectal flora in our community and the virulence of the most prevalent one. We will study the effect of combined standard antibiotic prophylaxis with and without the use of povidone iodine suppository prior to TRUS guided biopsy of the prostate in decreasing post biopsy complications specially infectious ones.

Chapter 1

ANATOMY OF THE PROSTATE

Gross anatomy:

The prostate gland is ovoid in shape (walnut), measures 3 cm in length, 4 cm in width, and 2 cm in depth and weighs 15-20 g. it lies below the urinary bladder where its base starts and prostate continues downwards till its most distal portion forming the apex at the level of urogenital diaphragm. The apex is in continuity with the striated urethral sphincter (**Fig. 1**)

A capsule made of collagen, Elastin and smooth muscle fibers encases the prostate except for the base and the apex and continues with the extension of the endopelvic fascia at the anterior and anterolateral surfaces of the prostate (*Epstein*, 1989).




Fig. (1): Normal prostate in vertical section (Ellis and Mahadevan, 2013).

Relations:

The prostate is fixed to the pubic bone anteriorly by the puboprostatic Ligaments near the apex of the prostate. The superficial branch of the dorsal vein is positioned in the retropubic fat outside the prostatic fascia. It drains into the dorsal vein complex.

The levator ani's pubococcygeal portion hugs the lateral aspects of the prostate and is related to its overlying endopelvic fascia. The prostate capsule and the pelvic fascia separate below the parietal and visceral endopelvic fascia juncture (**Fig. 2**).

Fatty, areolar tissue and the lateral branches of the dorsal vein complex take up the space of this separation between the prostate capsule and the pelvic fascia. The cavernosal nerves travel within the parietal pelvic fascia, also known as the lateral prostatic fascia, posterolateral to the prostate. Posteriorly, the prostate is related to ampulla of the rectum and pierced by ejaculatory ducts to open in prostatic urethra (*Walz J. et al.*, 2007).




Fig. (2): Cross section of prostate with prostatic fascial layersoutlined, including the lateral prostatic fascia (LPF), endopelvic fascia (EPF), levator ani fascia (LAF), Denonvilliers fascia (DF), anterior lamina of Denonvilliers fascia (ADF), posterior lamina of Denonvilliers fascia (PDF), neurovascular bundle (NVB), and lateral nerves (N) (*Walz J. et al.*, 2007).

Zonal anatomy:

The Prostate is divided into 3 distinct zones according to **McNeal's concept** of zonal architecture (*McNeal*, *1981*) (**Fig. 3**).

■ Transition zone. The transition zone comprises 5% to 10% of the glandular tissue of the normal prostate. It is separated from other glandular compartments by a fibromuscular band. It surrounds the proximal urethra and is the region of the prostate gland which grows throughout life and is commonly responsible for the disease of benign prostatic enlargement